...
首页> 外文期刊>American Journal of Cancer Research >Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method
【24h】

Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method

机译:微管靶向抗癌药物氟啶酮与人参衍生的具有细胞保护作用的人参三醇在体外对MX-1细胞的协同组合:组合指数法的实验设计和数据分析

获取原文
           

摘要

This brief article focuses on two aims: i) To investigate the in vitro pharmaco-dynamic interactions of combining synthetic potent microtubule targeting anticancer agent, Fludelone (FD) with cyto-protective agent, Panaxytriol (PXT) derived from Panax ginseng, and ii) To illustrate step-by-step operation for conducting two-drug combination in vitro using the combination index method, in terms of experimental design, data acquisition, computerized simulation and data interpretation. The Chou-Talalay method for drug combination is based on the median-effect equation, which provides the theoretical basis for the combination index (CI)-isobologram equation that allows quantitative determination of drug interactions, where CI<1, =1, and >1 indicates synergism, additive effect and antagonism, respectively. Based on these algorithms, computer software, CompySyn, is used for determining synergism and antagonism at all doses or effect levels simulated automatically. The use of Chou-Talalay’s CI method in quantifying synergism or antagonism is increasing steadily during the past two decades, however, confusing questions and pitfalls were still frequently raised by insufficient understanding of the theory, especially reflected when researchers trying to use the computerized software to design and conduct experiments. In order to specifically address the confusions and to illustrate the practical features of this method, in this paper, a selected example is given based on our unpublished data regarding the combinational pharmacologic interactions of FD and PXT against the growth of breast cancer cell line MX-1. The step-by-step operation from experimental design to the real data analysis is illustrated. The results indicated that FD and PXT combination in vitro exerted synergistic effect when cell growth inhibition was greater than 45%, with CI ranged 0.836-0.609 for the fractional inhibition of Fa=0.50~0.90, as shown by the Fa-CI plot and by the isobologram. Thus, quantitative conclusion of synergism is obtained using the Chou-Talalay CI method, under the well-defined simple conditions for the FD and PXT combinations in vitro.
机译:这篇简短的文章着重于两个目标:i)研究合成的有效微管靶向抗癌药Fludelone(FD)与细胞保护剂,人参衍生的人参三醇(PXT)的体外药效相互作用,以及ii)为了说明在实验设计,数据采集,计算机模拟和数据解释方面使用组合指数方法进行体外两种药物组合的分步操作。药物组合的Chou-Talalay方法基于中值效应方程式,该方程式为组合指数(CI)-等效线图方程式提供了理论基础,该方程式可以定量确定药物相互作用,其中CI <1,= 1和> 1分别表示协同作用,加和作用和拮抗作用。基于这些算法,计算机软件CompySyn用于确定自动模拟的所有剂量或效应水平下的协同作用和拮抗作用。在过去的二十年中,Chou-Talalay的CI方法用于量化协同作用或对抗性的趋势正在稳步增长,但是,由于对该理论的了解不足,仍然经常引起令人困惑的问题和陷阱,尤其是当研究人员试图使用计算机化软件设计和进行实验。为了具体解决这种困惑并说明该方法的实用功能,在本文中,根据我们尚未发表的有关FD和PXT的组合药理作用对乳腺癌细胞系MX-M的相互作用的研究,给出了一个选定的例子。 1。说明了从实验设计到实际数据分析的分步操作。结果表明,当细胞生长抑制率大于45%时,FD和PXT组合具有协同作用,Fa = 0.50〜0.90的部分抑制作用的CI范围为0.836-0.609,如Fa-CI图和等效线图。因此,在明确定义的简单FD和PXT组合体外简单条件下,可使用Chou-Talalay CI方法获得协同作用的定量结论。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号